Phase 4 Heart Disease Trial, Recruiting NCT07511257 Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT07511257
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 80 years old (any sex) who are in the hospital with a heart attack or similar urgent heart condition
  • The heart attack or urgent heart condition must have happened within the last 7 days before joining, shown by symptoms, an abnormal blood test for heart damage (troponin), and changes (or no changes) on a heart tracing (ECG)
  • The blood vessel that caused the heart problem must show a specific abnormality called coronary artery ectasia (an unusual widening of the artery), confirmed by two specialist heart doctors and a detailed imaging measurement
  • The hospital stay must be longer than 24 hours
  • Treatment can have included a procedure to open the blocked artery (such as a stent, balloon, or clot removal) or medication alone — both are acceptable
  • Must be willing and able to sign a consent form and take part in the study

Who may not be able to join:

  • Women who are pregnant
  • People who already need blood-thinning medication (anticoagulants) for another reason at the time of joining
  • People with severely reduced kidney function (a kidney filter rate below 30, either during the hospital stay or at the time of discharge)
  • People with a history of serious bleeding, current bleeding, or conditions that put them at high risk of bleeding (such as stomach bleeding or bleeding in the brain)
  • People with severely weakened heart pumping function (pump strength below 30%) combined with either: more than two hospital or emergency visits for heart failure in the past year, OR being significantly limited in daily activities by heart failure symptoms despite taking all recommended medications

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +52 5555732911

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Registry
ClinicalTrials.gov
Start date
11 February 2026
Est. completion
1 June 2029

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Time to First Major Adverse Cardiovascular Event (MACE); Time to First Bleeding Event According to the BARC Classification

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov